Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2000-03-07
2004-11-16
Nolan, Patrick J. (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S324000
Reexamination Certificate
active
06818618
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Area of the Art
The invention relates generally to the regulation of cell movement and specifically to the inhibition of smooth muscle cell (SMC) movement by Tenascin-C peptides.
2. Description of the Prior Art
Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citation for these references may be found at the end of this application, preceding the claims.
Neointima formation is a leading cause of the pathogenesis of vascular diseases such as atherosclerosis, restenosis following percutaneous transluminal coronary angioplasty (PTCA), and vein bypass atherosclerosis. Migration of vascular smooth muscle cells from media to intima plays a critical role in neointima formation (1-3). After surgical injury to the arterial integrity, activated smooth muscle cells migrate and then proliferate in the neointima (4). Accumulation of SMCs and deposition of an extracellular matrix lead to a hemodynamically compromising neointimal lesion, which is developed in a fraction of the time that is needed for the development of the primary atherosclerotic lesion (5). To prevent intimal hyperplasia, restenosis and atherosclerosis, the rapid accumulation of SMCs in the neointima must be inhibited (6).
Excessive SMC proliferation and migration occur as a result of growth factors produced by cellular constituents in the blood and the damaged arterial vessel wall which mediates the proliferation of SMCs in vascular restenosis. SMC migration may be activated by chemotactic agents, such as PDGF-BB and angiotensin II, and chemokinetic agents such as PDGF. Antibodies to growth factor PDGF may inhibit neointimal smooth muscle cell accumulation after angioplasty (6).
The SMC migration is mediated by interaction of SMC surface receptors and the extracellular matrix. The process of cell attachment to the matrix is frequently mediated by a family of cell-surface receptors called integrins (7). These receptors constitute a family of proteins with share structural characteristics of noncovalent, heterodimeric glycoprotein complexes including &agr; and &bgr; subunits. Integrin receptors are believed to form a link between the extracellular and intracellular environments and to affect cellular behavior by transmitting extracelluar signals to the intracellular compartment.
Some integrins recognize and bind to specific amino acid sequences within matrix macromolecules. For example, the integrin receptors on a number of cell types recognize an arginine-glycine-aspartic acid sequence (RGD) within the cell-binding domain of the extracelluar matrix proteins (8). The smooth muscle cell has at least six of these RGD-dependent integrins, including the fibronectin receptor &agr;
5
&bgr;
1
, the vitronectin receptor &agr;
v
&bgr;
3
, and the platelet glycoprotein IIb/IIIa, &agr;
IIb
&bgr;
IIIa
. Peptides that block integrin &agr;
v
&bgr;
3
can inhibit neointimal hyperplasia (9).
It has been observed that chemotactic factors, including PDGF-BB and angiotensin II, markedly induce Tenascin-C gene expression in SMCs (10, 11). Tenascin-C is an oligomeric glycoprotein composed of multiple domains that has been implicated in cell migration (12-18). Human, mouse, and chicken Tenascin-C contain a cysteine-rich segment at their amino termini through which the six Tenascin-C monomers link into a hexamer. This segment is followed by epidermal growth factor-like repeats, fibronectin-type III repeats (FN-L), and a globular carboxyl terminus, homologous to fibrinogen (Fbg-L) (19). These domains mediate the interaction between the Tenascin-C molecule and cells. For example, endothelial cells interact with Tenascin-C through its fibrinogen-like domain (20), whereas the FN-L domain of Tenascin-C mediates interaction with fibroblast (21).
However, the interaction of SMCs with Tenascin-C is unknown. Particularly, the specific domain of Tenascin-C that mediates its interaction with SMCs is unknown. It is desirable to study the molecular mechanism of Tenascin-C-SMC interactions, and therefore to provide agents that inhibit the migration of smooth muscle cells that are useful in the treatment and prevention of intimal hyperplasia, restenosis and atherosclerosis.
SUMMARY OF THE INVENTION
It is an object of the present invention to study the interaction of Tenascin-C with smooth muscle cells, and therefore to provide novel factors to regulate smooth muscle cell migration, and methods thereof.
One aspect of the present invention provides synthetic peptides derived from a Tenascin-C protein, wherein the polypeptides are capable of interacting with smooth muscle cells. In one embodiment of the present invention, the peptides are derived from the Fbg-L domain of the Tenascin-C protein.
Another aspect of the present invention provides a method of inhibiting the Tenascin-C protein mediated smooth muscle cell adhesion and migration. A method in accordance with the present invention comprises contacting the SMC with an effective amount of a factor capable of reducing the interaction of the SMC with the Tenascin-C protein. In one embodiment of the present invention, the factor is a peptide of the present invention. In another embodiment of the present invention, the factor is EDTA. In yet another embodiment of the present invention, the factor is an antibody against the Tenascin-C protein.
A further aspect of the present invention provides a method of inhibiting Tenascin-C mediated vascular smooth muscle cell adhesion and migration in a host. A method in accordance with the present invention comprises administering to the host in need of the inhibition an effective amount of a factor capable of reducing the interaction of the SMC with the Tenascin-C protein. In accordance with the present invention, the factor can be a peptide or an antibody of the present invention.
Yet another aspect of the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a factor capable of reducing the interaction of the SMC with the Tenascin-C protein, and a pharmaceutically acceptable carrier. In accordance with embodiments of the present invention, the factor can be a peptide or an antibody of the present invention.
The invention is defined in its fullest scope in the appended claims and is described below in its preferred embodiments.
REFERENCES:
patent: 5092885 (1992-03-01), Yamada et al.
patent: 5169930 (1992-12-01), Ruoslahti et al.
patent: 5246451 (1993-09-01), Trescony et al.
patent: 5512474 (1996-04-01), Clapper et al.
patent: 5622975 (1997-04-01), Singh et al.
patent: 5674848 (1997-10-01), Bhatnagar
patent: 5681931 (1997-10-01), Reid et al.
patent: 5684133 (1997-11-01), Schwab et al.
patent: 5710159 (1998-01-01), Voss et al.
patent: 94/21664 (1994-09-01), None
LaFleur et al. The FASEB Journal, vol. 12 p. A479, 1998.*
David W. LaFleur et al., “Aortic Smooth Muscle Cells Interact with Tenascin-C through its Fibrinogen-like Domain,”The Journal of Biological Chemistry, vol. 272, No. 52, pp. 32798-32803, 1997.
Gordon A.A. Ferns et al., “Inhibition of Neointimal Smooth Muscle Accumulation after Angioplasty by an Antibody to PDGF,”Science,vol. 253, No. 5024, pp. 1129-1132, 1991.
Eric T. Choi, et al., “Inhibition of neointimal hyperplasia by blocking &agr;&ngr;&bgr;3integrin with a small peptide antagonist GpenGRGDSPCA,”Journal of Vascular Surgery,vol. 19, No.1, pp. 125-134, 1994.
Daniel Kirchhofer et al., “&agr;2&bgr;1Integrins from Different Cell Types Show Different Binding Specificities,”The Journal of Biological Chemistry,vol. 265, No. 2, pp. 615-618, 1990.
Aarno Hautanen et al., “Effects of Modifications of the RGD Sequence and Its Context on Recognition by the Fibronectin Receptor,”The Journal of Biological Chemistry, vol. 264, No. 3, pp. 1437-1442, 1989.
Mario A. Bourdon et al., “Tenascin Mediates Cell Attachment through an RGD-dependent Receptor,”The
Cedars-Sinai Medical Center
Nolan Patrick J.
Pillsbury & Winthrop LLP
LandOfFree
Inhibition of smooth muscle cell migration by Tenascin-C... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of smooth muscle cell migration by Tenascin-C..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of smooth muscle cell migration by Tenascin-C... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3303271